Physician profile
Cheryl Aber
NPI 1740275312
$3,746.08
in general payments reported to CMS, 2019-2025
25 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $253 · 2021: $275 · 2022: $381 · 2023: $531 · 2024: $431 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $704.79 | 2019-2025 | Botox |
| Genzyme Corporation | $503.63 | 2019-2025 | |
| Pfizer INC. | $413.12 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $394.16 | 2019-2025 | Dupixent |
| Almirall LLC | $340.82 | 2019-2025 | Seysara |
| Allergan, INC. | $285.16 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $156.27 | 2019-2025 | |
| Galderma Laboratories, L.P. | $134.04 | 2019-2025 | Nemluvio |
| Organon LLC | $116.35 | 2025 | Nexplanon |
| Lilly USA, LLC | $113.40 | 2019-2025 | Ebglyss |
| Dermira, INC. | $89.36 | 2019-2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $69.81 | 2025 | Clear & Brilliant, Clear+Brilliant |
| Sun Pharmaceutical Industries INC. | $67.07 | 2022-2023 | Absorica Ld, Winlevi, Blu-U |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $64.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.18 | 2025 | Spevigo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $46.05 | 2019-2020 | |
| Celgene Corporation | $34.14 | 2019 | |
| Amgen INC. | $22.86 | 2025 | Otezla |
| Verrica Pharmaceuticals INC. | $22.43 | 2025 | Ycanth |
| Epi Health, LLC | $20.43 | 2019 | |
| Lnhc, INC | $18.74 | 2025 | Zelsuvmi |
| Biofrontera INC. | $18.27 | 2019 | |
| Incyte Corporation | $16.74 | 2023 | Opzelura |
| Janssen Biotech, INC. | $15.82 | 2019 | |
| Leo Pharma INC. | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Aber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.